GlassScriptPhysician profile
Keith R Wells
NPI 1083904304
$5,506.99
in general payments reported to CMS, 2019-2025
16 companies · $789 in 2025
The $789 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $11.75 · 2021: $186 · 2023: $3,204 · 2024: $1,316 · 2025: $789.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,520 · Food and Beverage: $1,058 · Honoraria: $1,000 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $731.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,520.00 |
| Food and Beverage | $1,057.59 |
| Honoraria | $1,000.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $731.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $1,220.00 | 2023 | Libtayo |
| Pharmaessentia USA Corporation | $1,100.00 | 2023 | Besremi |
| Karyopharm Therapeutics INC. | $1,100.00 | 2024 | Xpovio |
| Genmab U.S., INC. | $733.65 | 2023 | Epkinly |
| Abbvie INC. | $549.63 | 2024-2025 | |
| Biogen, INC. | $300.00 | 2023-2025 | Tysabri |
| Beone Medicines USA, INC. | $165.41 | 2025 | Brukinsa, Tevimbra |
| Alexion Pharmaceuticals, INC. | $150.00 | 2021 | |
| Aveo Pharmaceuticals, INC. | $89.43 | 2024-2025 | |
| Blueprint Medicines Corporation | $50.72 | 2025 | Ayvakit |
| Merck Sharp & Dohme LLC | $24.48 | 2021 | |
| Gilead Sciences, INC. | $11.92 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $11.75 | 2020 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Wells listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.